peptide purity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
The primary structure of Selank is Thr-Lys-Pro-Arg-Pro-Gly-Pro, corresponding to the molecular formula C33H57N11O9 and a monoisotopic mass of roughly 751.9 daltons. The N-terminal threonine and the arginine residue in the fourth position are shared with tuftsin, which carries the sequence Thr-Lys-Pro-Arg. The three additional residues at the C-terminus, Pro-Gly-Pro, extend the chain and are associated with greater resistance to enzymatic degradation. This extension also separates Selank from the shorter parent peptide.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Selank is a synthetic heptapeptide developed in Russia. Its sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, a seven-residue chain built around the natural tetrapeptide tuftsin. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences first described the compound in the mid-1990s. The design combined the tuftsin core with an added Pro-Gly-Pro tail, a modification intended to extend the molecule's stability in biological fluids. Published work on the peptide has appeared mainly in Russian-language journals.
Reported activity for Selank centers on anxiolytic and nootropic effects. Russian clinical reports describe use in anxiety and in cognitive or attention-related complaints. Most of this evidence comes from studies conducted by the same research groups that developed the peptide. Independent replication in other countries remains limited, and no major Western regulatory agency has approved the compound for any indication. The gap between local reports and external verification is a recurring point in discussions of the peptide.
Tuftsin, the parent structure, is a naturally occurring immunomodulatory tetrapeptide released from the Fc region of immunoglobulin G by spleen enzymes. Selank extends this four-residue sequence with three additional amino acids. The stated rationale is that the added tail slows enzymatic breakdown and may influence receptor interactions. How the full heptapeptide behaves at the molecular level is not firmly established, and proposed mechanisms often involve indirect modulation of neurotransmitter or immune signaling rather than a single defined target.
Identity and purity of selank are established with reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The peptide elutes from C18 columns with acetonitrile gradients in water containing trifluoroacetic acid or formic acid, and detection is usually performed by ultraviolet absorbance near 214 nm. Electrospray ionization in positive mode gives a doubly protonated ion near m/z 377, consistent with a mass of about 752 Da. Amino acid analysis or tandem mass spectrometry of fragment ions confirms the sequence. Because the molecule has no aromatic residues, it lacks a usable 280 nm chromophore, so low-wavelength detection or mass spectrometry is required.
Peptide bonds in selank are susceptible to hydrolysis under strongly acidic or basic conditions, and the terminal proline residues are vulnerable to exopeptidase activity in biological samples. Lyophilized powder stored dry at -20 °C typically remains stable for extended periods, whereas aqueous solutions degrade faster and may lose measurable purity within days to weeks depending on pH, temperature, and microbial load. Repeated freeze-thaw cycles promote aggregation and adsorption to container surfaces. For analytical work, solutions are usually prepared fresh, kept cold, and used within a single working day.
Purity assessment relies mainly on reverse-phase high-performance liquid chromatography with ultraviolet detection. Because the peptide lacks a strong chromophore, detection often uses backbone absorbance near 214 nm. Identity is confirmed by mass spectrometry, typically electrospray ionization or matrix-assisted laser desorption, comparing the measured mass against the expected value. Amino acid analysis can verify composition after acid hydrolysis. Diastereomer content and residual counterions are reported less often, although both can influence biological assays.
Lyophilized material is generally stable for extended periods when kept dry at or below minus twenty degrees Celsius. Working solutions are less stable, and common practice is to aliquot and freeze them so that repeated freeze-thaw cycles are avoided. Aqueous solutions are sensitive to pH extremes and to microbial growth, so short-term storage at refrigerator temperature is typical. Oxidation and hydrolysis are the principal degradation routes. Reconstitution with sterile water or a mild buffer is standard, and solutions should be protected from light.
Larger oil companies are reportedly less interested in investing in Venezuela due to high investment costs and the country's political instability, while the smaller companies that are most interested have been described by industry officials as the "least prepared and least sophisticated" firms to do so.
=== Nuclear Magnetic Resonance Spectroscopy === NMR spectroscopy plays a crucial role in characterizing cage formation and dynamics in solution. Solution-state NMR allows researchers to monitor reaction progress and confirm structural features through chemical shift analysis and coupling patterns. Two-dimensional NMR techniques help establish connectivity patterns and verify the successful formation of key structural features. This solution-phase characterization complements solid-state analysis by providing insight into the cage's behavior under practical application conditions.
Following the approval of eteplirsen, two other drugs of a similar kind, golodirsen and viltolarsen received provisional approval from the FDA for the treatment of people with a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping as well as casimersen for exon 45 skipping.
The Fat Duck is a fine dining restaurant in Bray, Berkshire, England, owned by the chef Heston Blumenthal. Housed in a 16th-century building, the Fat Duck opened on 16 August 1995. Although it originally served food similar to a French bistro, it soon acquired a reputation for precision and innovation, and has been at the forefront of many modern culinary developments, such as food pairing, flavour encapsulation and multi-sensory cooking. The number of staff in the kitchen increased from four when the Fat Duck opened to 42, resulting in a ratio of one kitchen staff member per customer. The Fat Duck gained its first Michelin star in 1999, its second in 2002 and its third in 2004, making it one of eight restaurants in the UK to earn three Michelin stars. In 2005, the World's 50 Best Restaurants named the Fat Duck the best restaurant in the world. It lost its stars in 2016 when it closed for renovation, but regained all three the following year. The Fat Duck is known for its tasting menu featuring dishes such as nitro-scrambled egg and bacon ice cream, an Alice in Wonderland–inspired mock turtle soup involving a bouillon packet made up to look like a fob watch dissolved in tea, and a dish called Sound of the Sea which includes an audio element. It has an associated laboratory where Blumenthal and his team develop new dish concepts. In 2009, the Fat Duck suffered from the largest norovirus outbreak ever documented at a restaurant, with more than 400 diners falling ill.
Sources: en.wikipedia.org
== External links == EINECS number 249-946-8 Shippy, R Andrew; Mendez, Douglas; Jones, Kristina; Cergnul, Irene; Karpiak, Stephen E (2004). "S-Adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS". BMC Psychiatry. 4 38. doi:10.1186/1471-244X-4-38. PMC 535560. PMID 15538952.
Silverside is a cut of beef from the hindquarter of cattle, just above the leg cut. Called "silverside" in the UK, Ireland, South Africa, Australia and New Zealand, it gets the name because of the "silverwall" on the side of the cut, a long fibrous "skin" of connective tissue (epimysium) which has to be removed as it is too tough to eat. The primary muscle is the biceps femoris. Silverside is boned out from the top along with the topside and thick flank. In most parts of the U.S., this cut is known as outside or bottom round, or rump roast (which means something different in countries using the British beef cut scheme).
== Research == Beyond acute promyelocytic leukemia (APL), research is exploring arsenic trioxide’s antitumor effects in solid tumors such as glioma, where it induces cancer cell death by regulating apoptosis and autophagy, promoting oxidative stress within tumor cells, and inhibiting tumor stem cells.
Sources: en.wikipedia.org
=== 16 January === German Defence Minister Christine Lambrecht resigned in part due to blunders over German support for Ukraine. A grenade exploded in Tonenkoye village's community center, which was used to store ammunition and house Russian soldiers. TASS reported that the RGD-5 grenade explosion in Belgorod Oblast killed 3 soldiers and wounded 16. Eight soldiers were missing. Russia secured control of Soledar after capturing the last industrial zone near mine number 7 from Ukrainian troops. Ukraine admitted that they had lost Soledar.
1950: Fujirebio (formerly Fujizoki Pharmaceutical, Co., Inc.) is founded in Tokyo, Japan. 1966: Launch of HA Ag (TPHA), the world's first hemagglutination test for syphilis. 1981: Established Fujirebio Taiwan Inc. 1987: Established Fujirebio America, Inc. (merged to Fujirebio Diagnostics, Inc.) in the United States. 1998: Acquisition of Centocor Diagnostics of Pennsylvania, Inc. (USA, currently Fujirebio Diagnostics, Inc.), pioneer in oncology testing and developer of CA125II, CA19-9 and CA15-3. 2006: Acquisition of CanAg Diagnostics AB (Sweden, currently Fujirebio Diagnostics AB), leader in oncology biomarker development. 2007: Launch of CL4800 in Japan to support blood screening for the Japanese Red Cross Society (~2019). 2008: Acquisition of Advanced Life Science Institute, Inc. 2008: Acquisition of American Biological Technologies, Inc. (merged to Fujirebio Diagnostics, Inc.). 2010: Acquisition of Innogenetics N.V. (Belgium, currently Fujirebio Europe N.V.), world leader in specialty molecular and immunoassay testing. 2017: Established Fujirebio Holdings, Inc., as parent company of Fujirebio Inc., Fujirebio Diagnostics, Inc., Fujirebio Europe N.V. and other Fujirebio group companies. 2019: Established Fujirebio Diagnostics Japan, Inc., focusing on OEM business in Japan. 2020: Established Fujirebio China Co., Ltd. 2022: Acquisition of ADx NeuroSciences. 2022: Acquisition of Fluxus, Inc. 2025: Acquisition of Plasma Services Group, Inc.
== Clinical potential == β-Peptides are stable against proteolytic degradation in vitro and in vivo, a potential advantage over natural peptides. β-Peptides have been used to mimic natural peptide-based antibiotics such as magainins, which are highly potent but difficult to use as drugs because they are degraded by proteolytic enzymes.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
Reports describe modulation of GABA signalling, changes in monoamine turnover and effects on neurotrophic factor expression. These observations come mainly from animal and cell studies. A single unifying mechanism has not been demonstrated.